Total Payments
$476,919
2024 Payments
$36,629
Companies
21
Transactions
599
Medicare Patients
1,450
Medicare Billing
$231,487
Payment Breakdown by Category
Other$367,602 (77.1%)
Consulting$47,284 (9.9%)
Travel$39,771 (8.3%)
Food & Beverage$18,124 (3.8%)
Research$3,703 (0.8%)
Education$435.30 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $360,852 | 126 | 75.7% |
| Consulting Fee | $47,284 | 18 | 9.9% |
| Travel and Lodging | $39,771 | 116 | 8.3% |
| Food and Beverage | $18,124 | 308 | 3.8% |
| Honoraria | $6,750 | 2 | 1.4% |
| Unspecified | $3,703 | 17 | 0.8% |
| Education | $435.30 | 12 | 0.1% |
Payments by Type
General
$473,216
582 transactions
Research
$3,703
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $187,836 | 177 | $0 (2024) |
| EMD Serono, Inc. | $160,342 | 212 | $0 (2024) |
| Biogen, Inc. | $33,884 | 54 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $17,511 | 27 | $0 (2024) |
| Celgene Corporation | $16,697 | 32 | $0 (2024) |
| Genentech USA, Inc. | $16,331 | 16 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $13,293 | 13 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $8,645 | 6 | $0 (2023) |
| Horizon Therapeutics plc | $7,489 | 13 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $6,701 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36,629 | 77 | EMD Serono, Inc. ($29,464) |
| 2023 | $44,994 | 56 | EMD Serono, Inc. ($37,079) |
| 2022 | $36,544 | 66 | EMD Serono, Inc. ($25,067) |
| 2021 | $21,623 | 32 | EMD Serono, Inc. ($7,628) |
| 2020 | $25,870 | 53 | Celgene Corporation ($12,844) |
| 2019 | $54,036 | 69 | GENZYME CORPORATION ($37,775) |
| 2018 | $106,190 | 76 | GENZYME CORPORATION ($78,263) |
| 2017 | $151,033 | 170 | GENZYME CORPORATION ($59,700) |
All Payment Transactions
599 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/18/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $12.16 | General |
| 12/18/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $5.78 | General |
| 12/17/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: Neurology | ||||||
| 12/16/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Neurology | ||||||
| 12/16/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $1.56 | General |
| Category: Neurology | ||||||
| 12/11/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,795.00 | General |
| Category: Neurology | ||||||
| 12/10/2024 | ARGENX US, INC. | VYVGART (Drug), VYVGART HYTRULO | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Immunology | ||||||
| 12/05/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,795.00 | General |
| Category: Neurology | ||||||
| 12/05/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/05/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/04/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Neurology | ||||||
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $121.21 | General |
| 12/03/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $120.00 | General |
| Category: Neurology | ||||||
| 11/27/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $10.91 | General |
| 11/19/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $123.69 | General |
| 11/18/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $1.82 | General |
| Category: Neurology | ||||||
| 11/15/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Neurology | ||||||
| 11/13/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Travel and Lodging | Cash or cash equivalent | $623.95 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 11/12/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.74 | General |
| Category: Neuroscience | ||||||
| 10/30/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 10/30/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 10/30/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: Central Nervous System | ||||||
| 10/07/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: Neurology | ||||||
| 10/04/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Evaluating the Long-Term Outcomes and Durability of Effect following treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV ambispective study of patients who previously participated in the CLARITY/CLARITY-EXT and ORACLE Trials | EMD Serono, Inc. | $970.00 | 3 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),An Extension Protocol for Multiple Scerlosis Patients Who Participated in Gen | GENZYME CORPORATION | $472.94 | 1 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $472.94 | 1 |
| MS700568-0026 | EMD Serono, Inc. | $464.06 | 6 |
| Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study Two (CARE-MS II): A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and Hig | GENZYME CORPORATION | $443.33 | 2 |
| Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study Two (CARE-MS II): A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles ,of Intravenous Low- and | GENZYME CORPORATION | $333.33 | 1 |
| A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $187.06 | 1 |
| A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) | GENZYME CORPORATION | $182.61 | 1 |
| Comparison of alemtuzumab and Rebif efficacy in multiple sclerosis, study two (CARE-MS II): a phase 3, randomized, rater- and dose-blind study comparing two annual cycles of intravenous low- and high- | GENZYME CORPORATION | $176.67 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 351 | 450 | $174,436 | $40,471 |
| 2022 | 4 | 343 | 459 | $168,347 | $40,149 |
| 2021 | 7 | 385 | 8,412 | $278,518 | $85,683 |
| 2020 | 8 | 371 | 6,175 | $175,036 | $65,184 |
Total Patients
1,450
Total Services
15,496
Medicare Billing
$231,487
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 148 | 194 | $77,600 | $18,109 | 23.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 145 | 198 | $60,984 | $13,048 | 21.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 46 | 46 | $30,452 | $7,453 | 24.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 12 | $5,400 | $1,862 | 34.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 142 | 187 | $77,296 | $17,958 | 23.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 153 | 206 | $63,448 | $13,395 | 21.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $21,300 | $6,340 | 29.8% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 15 | 33 | $6,303 | $2,457 | 39.0% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 14 | 7,900 | $94,800 | $37,679 | 39.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 147 | 208 | $86,834 | $20,384 | 23.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 142 | 201 | $56,188 | $13,622 | 24.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 40 | 40 | $22,630 | $7,349 | 32.5% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Office | 2021 | 15 | 36 | $6,636 | $2,746 | 41.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 14 | $5,586 | $2,148 | 38.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $5,844 | $1,757 | 30.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 14 | 5,718 | $68,616 | $27,230 | 39.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 121 | 167 | $46,927 | $15,411 | 32.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 110 | 145 | $23,859 | $8,102 | 34.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 60 | 61 | $9,762 | $4,646 | 47.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 17 | 17 | $9,112 | $3,118 | 34.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 16 | 16 | $6,848 | $2,333 | 34.1% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Office | 2020 | 14 | 32 | $4,832 | $2,317 | 47.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 19 | 19 | $5,080 | $2,026 | 39.9% |
About Dr. Donald Barone, DO
Dr. Donald Barone, DO is a Neurology healthcare provider based in Camden, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1396933768.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Donald Barone, DO has received a total of $476,919 in payments from pharmaceutical and medical device companies, with $36,629 received in 2024. These payments were reported across 599 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($360,852).
As a Medicare-enrolled provider, Barone has provided services to 1,450 Medicare beneficiaries, totaling 15,496 services with total Medicare billing of $231,487. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Camden, NJ
- Active Since 10/10/2007
- Last Updated 05/01/2019
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1396933768
Products in Payments
- AUBAGIO (Drug) $107,494
- LEMTRADA (Drug) $77,107
- Mavenclad (Drug) $66,941
- Rebif (Biological) $42,974
- MAVENCLAD (Drug) $26,961
- TECFIDERA (Drug) $25,846
- ZEPOSIA (Drug) $20,780
- COPAXONE (Drug) $17,497
- Betaseron (Drug) $13,293
- OCREVUS (Biological) $9,383
- UPLIZNA (Drug) $7,489
- Non-Covered Product (Drug) $6,728
- Ponvory (Drug) $6,701
- Mavenclad (Biological) $5,215
- PONVORY (Drug) $4,833
- TYSABRI (Biological) $1,954
- SOLIRIS (Drug) $1,334
- LEMTRADA (Biological) $543.32
- UPLIZNA (Biological) $425.35
- Rystiggo (Drug) $315.73
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Camden
Dr. Olga Thon, M.d, M.D
Neurology — Payments: $330,128
Neurology $330,128
Dr. Evren Burakgazi-Dalkilic, M.d, M.D
Neurology — Payments: $113,843
Neurology $113,843
Amy Colcher, Md, MD
Neurology — Payments: $11,029
Neurology $11,029
Dr. Cristian Constantinescu, Md, Phd, MD, PHD
Neurology — Payments: $6,015
Neurology $6,015
Dr. Jesse Thon, M.d, M.D
Neurology — Payments: $3,729
Neurology $3,729
Dr. Swarna Rajagopalan, M.d, M.D
Neurology — Payments: $2,260
Neurology $2,260